Published today in the Official Gazette, the resolution outlines a relationship of 32 competent bodies and entities that will contribute to the development of the agenda in the state of São Paulo

Rômison Rodrigues Mota leaves the position after a request for review delays the norm's vote; the topic will return to the regulatory agenda for 2026-2027

With limited spots available, Cannabis Connection 2025 will host the launch of the 5th Sechat Cannabis Guide and discussions on regulation, cultivation, and market

The transformation of the scenario of access to cannabis treatment was promoted by people who understood the struggle of patients

The safety and efficacy of cannabis-based products depend on an integrated chain involving chemists, biomedicals, pharmacists, and doctors — professionals who ensure, at each stage, the quality, stability, and trust in patient treatment

The medicinal use of the plant advances and points to benefits in the treatment of pathologies in animals

Prohibition costs R$ 51 billion annually and contributes to the incarceration of Black and poor populations, highlights report

We should witness changes in RDC 327, flexibility in the pharmaceutical form of products, a new resolution from CFM, but this agenda is unlikely to progress in Congress.

Public hearing discusses legal support for entities that cultivate and distribute cannabis for therapeutic purposes

Agency requests that the court authorize the association to produce plant extract intended for patient treatment

The event organized by Revivid Brasil is free to attend and will feature lectures from prominent figures in the Brazilian cannabis scene

UFSC course trains health professionals on the endocannabinoid system, opening opportunities for therapeutic use of cannabis

CFQ member comments on the work that can be done in favor of the Brazilian cannabis scenario

Understand the positioning of the legislation and the Federal Council of Physiotherapy regarding the role of physiotherapists in prescribing medicinal cannabis, as well as the challenges faced in practice.

In his debut column for Sechat, veterinarian Erik Amazonas evaluates the latest statement issued by the Federal Council of Veterinary Medicine (CFMV) regarding the prescription of cannabis-derived products.

Move from Schedule I to Schedule III could unlock research, ease fiscal obstacles, and impact state markets

What to expect in the coming years regarding the cannabis agenda and what some lawmakers say about the development of the topic from now on

Authored by Deputy João Carlos Bacelar Batista (Pode-BA), the Bill 369/2021, which provides for the veterinary use of Cannabis sativa and its derivatives, has been under consideration in the Chamber since February. In line with the substitute for PL 399/2015, the proposal that

“The scenario has improved for the associations, but so what?” Questions the president of the Santa Cannabis patients' association when demanding more dialogue from regulatory agencies and associations regarding the new political scenario

Main meeting point for the Medicinal and Industrial Cannabis industry in Latin America starts at 4pm